论文部分内容阅读
目的构建以恶性疟原虫红内期重要的疫苗候选抗原——裂殖子表面蛋白１（ＭＳＰ１）羧基端编码分子量４２０００蛋白的基因片段为外源基因的可用作候选核酸疫苗的真核表达载体。方法目前对疟疾核酸疫苗的研究仅见于鼠疟，将恶性疟原虫ＦＵＰ株裂殖子表面蛋白１羧基端编码４２０００蛋白的基因片段用常规分子克隆方法，分别克隆入非分泌性真核表达载体ＶＲ１０１２和改建后的分泌型载体ＶＲ１０１２／ＴＰＡ中，通过ＰＣＲ和酶切鉴定出重组克隆。结果成功地构建了真核表达载体ＶＲ１０１２／ＭＳＰ１－４２和ＶＲ１０１２／ＴＰＡ／ＭＳＰ１－４２。结论目前对疟疾核酸疫苗的研究仅见于鼠疟红外期，该研究对研制有效的恶性疟原虫红内期核酸疫苗是一个有益的尝试。其免疫保护作用待进一步研究。
OBJECTIVE: To construct a eukaryotic expression vector that can be used as a candidate nucleic acid vaccine with the gene fragment encoding the molecular weight of 42000 at the carboxyl terminus of an important vaccine candidate antigen of Plasmodium falciparum-red meropenem (MSP1) . Methods The present study of malaria nucleic acid vaccine was only found in murine malaria. The gene fragment coding for the 42000 protein at the carboxyl terminus of the Fusarium surface Plasmid 1 of Plasmodium falciparum was cloned into the non-secretory eukaryotic expression vector VR1012 And the reconstructed secretory vector VR1012 / TPA, recombinant clones were identified by PCR and restriction enzyme digestion. Results The eukaryotic expression vectors VR1012 / MSP1-42 and VR1012 / TPA / MSP1-42 were successfully constructed. Conclusion At present, the research on malaria nucleic acid vaccine is only found in the murine malaria IR. This study is a beneficial attempt to develop an effective malaria parasite intra-red nucleic acid vaccine. Its immune protection needs further study.